Close

CMS, Inc., receives FDA 510(k) clearence for Atlas-Based Autosegmentation software

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...

Thermo Fisher Receives FDA Approval for...

The world leader when it comes to serving science,...

Virtual MRI Imaging with AI Aids...

During the magnetic resonance imaging (MRI) procedures, contrast agents...
CMS, Inc., an Elekta Company, and worldwide leader in radiation treatment planning and workflow management solutions, has received FDA 510(k) clearance for its new Atlas-Based Autosegmentation (ABAS) product.

CMS, Inc., an Elekta Company, and worldwide leader in radiation treatment planning and workflow management solutions, has received FDA 510(k) clearance for its new Atlas-Based Autosegmentation (ABAS) product. This clearance allows CMS to immediately begin distributing Atlas-Based Autosegmentation for clinical use in the United States.

Significantly reducing the amount of time spent creating and editing patient contours, ABAS is a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan. Image segmentation, or contouring, is a time consuming component of the treatment planning process, and ABAS helps save clinicians time by providing a good starting point from which minimal editing is required.

In addition to its time-saving benefits, ABAS distinguishes itself from competing products in several ways. A stand-alone, vendor-neutral product that communicates using standard DICOM file formats for both input and output, ABAS is compatible with any radiation treatment planning system that can read standard DICOM RT structure set files.

Terry Wolf, Director of Research for CMS, an Elekta Company said, We are extremely proud and very pleased to receive clearance to distribute Atlas-Based Autosegmentation to the U.S. market.  An embodiment of our core values, ABAS is an innovative solution delivered in a vendor-neutral platform aimed at improving the quality of care.

The ABAS algorithms were developed by Dr. Xiao Han, CMS Research Scientist. Dr. Han’s work, titled, Atlas-based Auto-segmentation of Head and Neck CT Images, will be presented September 9 at the 11th Annual International Conference on Medical Image Computing and Computer Assisted Intervention in New York City.

Latest stories

Related stories

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Virtual MRI Imaging with AI Aids Better Tumor Detection

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back